Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05168735 · ClinicalTrials.gov registry record · Phase 1

Ketamine + Mindfulness for Depression

A Phase 1 study of Depression, Unipolar, sponsored by Rebecca Price.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
1
Study location

NCT05168735 is a Phase 1 study of Depression, Unipolar that has completed, run by Rebecca Price. The registered enrollment target is 43 participants, below the 317-participant average among 3 other Depression, Unipolar trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05168735, a Phase 1 study of Depression, Unipolar, has completed, sponsored by Rebecca Price.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.

Conditions Studied

Interventions

  • DRUG Intravenous Ketamine
  • BEHAVIORAL Brief Mindfulness Exercises
  • BEHAVIORAL Academic Exercises

Study Locations (1)

Pennsylvania

  • Western Psychiatric Institute and Clinic - Pittsburgh

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2022-02-01
Est. Completion 2023-09-01
Phase Phase 1

Sponsor

Rebecca Price

7 total trials

What the Registry Record Tells You About NCT05168735

The ClinicalTrials.gov registry entry for NCT05168735 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 317-participant average among 3 other Depression, Unipolar trials with a reported enrollment target (86% lower). The listed sponsor is Rebecca Price, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression, Unipolar appearing as the primary indexed condition, and to 3 interventions - of which Intravenous Ketamine is the first listed.

NCT05168735 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05168735 about?

NCT05168735 is a clinical study titled "Ketamine + Mindfulness for Depression". In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the c...

What is the current status of trial NCT05168735?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-02-01. Estimated completion is 2023-09-01.

What conditions does trial NCT05168735 study?

This clinical trial studies the following conditions: Depression, Unipolar.

What interventions are being tested in trial NCT05168735?

The interventions under investigation include: Intravenous Ketamine (DRUG), Brief Mindfulness Exercises (BEHAVIORAL), Academic Exercises (BEHAVIORAL).

Who is sponsoring clinical trial NCT05168735?

This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05168735 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression, Unipolar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.